MINOR APPLICATIONS
| HEALTH TECHNOLOGY | VASOPRESSIN | SAMBONG 250 MG TABLET | VARENICLINE | NICOTINE REPLACEMENT THERAPY | 2.5% PERITONEAL DIALYSIS SOLUTION | 0.1% SODIUM HYALURONATE (15 ML) |
| PROPONENT | DOH Disease Prevention and Control Bureau | Philippine Institute of Traditional and Alternative Health Care (PITAHC) | DPCB - Lifestyle-Related Diseases Division | DPCB - Lifestyle-Related Diseases Division | Philippine General Hospital, National Kidney and Transplant Institute | Asian Eyes Optical |
| TOPIC NOMINATION | ||||||
| APPRAISAL AND RECOMMENDATION | ||||||
| APPEALS ON PRELIMINARY HTAC RECOMMENDATION | ||||||
| FINAL RECOMMENDATION | 28 February 2022 | 14 January 2022 | 17 May 2021 | 17 May 2021 | 17 February 2021 | 10 March 2021 |
| DECISION OF THE SECRETARY OF HEALTH | 02 March 2022 | 14 January 2022 | 17 May 2021 | 17 May 2021 | 19 February 2021 | 10 March 2021 |
| DISSEMINATION | Link to HTAC Recommendation | Link to HTAC Recommendation | Link to issuance | Link to issuance | Link to Issuance | Link to Issuance |
URGENT HTA TRACK
| HEALTH TECHNOLOGY | ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) | TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR | DOLUTEGRAVIR | INACTIVATED POLIOVIRUS VACCINE (IPV) (TRANSITION FROM ONE- TO TWO-DOSE) | 10- AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES (PCV) (REASSESSMENT) |
| PROPONENT | National AIDS and STI Prevention and Control Program - Philippines (NASPCP) | National AIDS and STI Prevention and Control Program - Philippines (NASPCP) | National AIDS and STI Prevention and Control Program - Philippines (NASPCP) | DOH National Immunization Program | DOH National Immunization Program |
| TOPIC NOMINATION | |||||
| TOPIC PRIORITIZATION | |||||
| SCOPING AND PROTOCOL DEVELOPMENT | |||||
| ASSESSMENT | |||||
| EVIDENCE APPRAISAL | |||||
| PRELIMINARY RECOMMENDATION | |||||
| APPEALS | |||||
| RESOLUTION | |||||
| FINAL RECOMMENDATION | 17 December 2017 | 09 August 2021 | 21 September 2021 | 13 July 2021 | 14 August 2020 |
| DECISION OF THE SECRETARY OF HEALTH | 18 January 2022 | 01 September 2021 | 28 September 2021 | 10 September 2021 | 14 August 2020 |
| DISSEMINATION | Link to issuanceLink to Evidence Summary | Link to Evidence Summary and Issuance | Link to Evidence Summary and Issuance | Link to issuanceLink to Evidence Summary | Link to IssuanceLink to Evidence Summary |
GENERAL HTA TRACK
| Name of Drug | Status |
|---|---|
| Aflibercept for wet age-related macular degeneration | For External Commissioning |
| Dexamethasone for diabetic macular edema | For External Commissioning |
| Ranibizumab for visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) | For External Commissioning |
| Sitagliptin for Uncontrolled Type 2 Diabetes Mellitus | For External Commissioning |
| TACE with Mitomycin C for patients with non-resectable Hepatocellular Carcinoma | For External Commissioning |
| Insulin aspart (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus | For External Commissioning |
| Insulin glulisine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus | For External Commissioning |
| Insulin lispro (Mix - P 814 3ml pre-filled pen (100 U/mL); Insulin Lispro 100 Units/mL, 10 ml vial) | For External Commissioning |
| Pazopanib as treatment for Renal Cell Carcinoma | For External Commissioning |
| Sunitinib for Renal Cell Carcinoma | For External Commissioning |
| Pertuzumab for HER2+ Breast Cancer | For finalization of recommendation after appeals |
| Rituximab SC for Non-Hodgkin’s Lymphoma | For finalization of recommendation after appeals |
| Eribulin for Metastatic Soft Tissue Sarcoma (mSTS) | For finalization of recommendation after appeals |
| Eltrombopag olamine in the treatment of refractory thrombocytopenia among patients with chronic immune thrombocytopenia (ITP) | On-going assessment |
| Abiraterone for adult men with prostate cancer | On-going assessment |
| Dabigatran for myocardial infarction with atrial fibrillation | On-going assessment |
| Dapagliflozin (5mg/10 mg tablet) for adult patients with Type 2 Diabetes Mellitus patients inadequately controlled on metformin monotherapyDapagliflozin | On-going assessment |
| Enzalutamide (40mg soft gel capsule) for adult men with metastatic castration-resistant prostate cancer (mCRPC) | On-going assessment |
| Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus | For finalization of recommendation after appeals |
| Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus | For finalization of recommendation after appeals |
| Rivaroxaban for myocardial infarction with atrial fibrillation | On-going assessment |
| Zoledronic acid for prevention of skeletal-related events in cancer patients | On-going assessment |
| Cerebrolysin for patients with acute ischemic stroke, dementia and traumatic brain injury | On-going assessment |
| Citicoline for acute and recovery phase of cerebral infarction (e.g., ischemia due to stroke) | On-going assessment |
| Nilotinib as first-line treatment for Chronic Phase-Chronic Myeloid Leukemia | On-going assessment |
| Ivabradine for the treatment of stable angina pectoris among adult patients with coronary artery disease | On-going assessment |
| Ticagrelor for the prevention of thrombotic events among patients with Acute Coronary Syndrome | On-going assessment |
| Tirofiban HCl for treatment of unstable angina or non-Q wave myocardial infarction | For External Commissioning |
EXPEDITED HTA TRACK (COVID-19 VACCINES)
| PROCESS | PEDIA VACCINATION 5 to 11 YRS OLD | PEDIA VACCINATION 12 to 17 YRS OLD | BOOSTER AND ADDITIONAL DOSE | PFIZER | ASTRAZENECA | SINOVAC | SPUTNIK V | JOHNSON & JOHNSON | MODERNA | COVOVAX | COVAXIN | SINOPHARM |
| EUA Approval | ||||||||||||
| Data Extraction and Synthesis | ||||||||||||
| HTAC Recommendation | ||||||||||||
| Decision of Secretary of Health | ||||||||||||
| Dissemination | Link to Evidence Summary | Link to Evidence Summary | Link to Evidence Summary | Version 1 | Version 1 | Link to Evidence Summary | Version 1 | Version 1 | Link to Evidence Summary | Link to Evidence Summary | Link to Evidence Summary | Link to Evidence Summary |
| Version 2 | Version 2 | Link to Evidence Summary | Version 2 | Version 2 | ||||||||
| Version 3 |
EXPEDITED HTA TRACK (COVID-19 INVESTIGATIONAL DRUGS)
| HEALTH TECHNOLOGY | CASIRIVIMAB+INDEVIMAB | DEXAMETHASONE | FAVIPIRAVIR | REMDESIVIR | BARICITINIB | TOCILUZIMAB |
| PROPONENT | Disease Prevention and Control Bureau (DPCB) | Philippine Academy of Ophthalmology | DOH Disease Prevention and Control Bureau | DOH Disease Prevention and Control Bureau | DOH Disease Prevention and Control Bureau | DOH Disease Prevention and Control Bureau |
| TOPIC NOMINATION | ||||||
| TOPIC PRIORITIZATION | ||||||
| ASSESSMENT | ||||||
| RECOMMENDATION | ||||||
| DECISION OF THE SECRETARY OF HEALTH | ||||||
| DISSEMINATION | Link to HTAC Recommendation | Link to Signed Endorsement Letter and Evidence Summary | DexamethasoneLink to issuance | DexamethasoneLink to issuance | DexamethasoneLink to issuance | DexamethasoneLink to issuance |
EXPEDITED HTA TRACK (COVID-19 DIAGNOSTICS)